Monday, June 22, 2020 3:12:13 PM
Recently spoke with DI regarding the DL and TLD and their previously communicated timelines. He confirmed that they stand by their timelines. Based on the discussion, and IMHO, my prediction is:
- We will see a PR THIS WEEK that provides confirmation of DL, and may include reference that it's not 100% of the data but they intend to remain on schedule. This will call for a "soft lock", with a plan to update the data when it's complete.
- They will provide an update to the TLD timelines and that due to COVID-19 continuing to limit hospital access, resulting in the "soft lock", the original schedule of end-of-June to early-July will still be July, but more likely mid- to late-July.
It's rather frustrating that if they do a soft lock, they should have done it earlier in order to submit an abstract for the June 8th SNO deadline. However, in this virtual conference world that we live in, it may not be necessary to announced results at a conference, but rather with a strong press release aligned with the publication in a high-impact journal.
- We will see a PR THIS WEEK that provides confirmation of DL, and may include reference that it's not 100% of the data but they intend to remain on schedule. This will call for a "soft lock", with a plan to update the data when it's complete.
- They will provide an update to the TLD timelines and that due to COVID-19 continuing to limit hospital access, resulting in the "soft lock", the original schedule of end-of-June to early-July will still be July, but more likely mid- to late-July.
It's rather frustrating that if they do a soft lock, they should have done it earlier in order to submit an abstract for the June 8th SNO deadline. However, in this virtual conference world that we live in, it may not be necessary to announced results at a conference, but rather with a strong press release aligned with the publication in a high-impact journal.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
